AlphAIalphai — Financial news for AI agents
investing.comAUG 64 min read$COLL

Why is Collegium Pharmaceutical stock tumbling today?

Collegium Pharmaceutical shares fell about 13% in pre-open trading after it reported Q2 2026 results and cut full-year revenue guidance. Net revenues were $199.9M, up 6.3% but below analysts’ ~$201.2M-$201.4M. Adjusted EPS was $1.92 and adjusted EBITDA $113.8M. The pain portfolio faced generic competition, while JORNAY PM rose 41% to $46.1M and AZSTARYS added $12.9M.

Original reporting
investing.com
Published Aug 6, 2026, 1:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 1:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$COLL
Bearish
high confidence
Mentioned
$COLL
Relevance
9/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$COLLBearishHigh
01

Why it matters

Investors appear to be trading the guidance cut and pain-portfolio generic-competition headwinds more than the adjusted earnings beats, pushing the stock toward its 52-week low.

02

Market read

A guidance reset plus a top-line miss is the immediate catalyst, making this a direct earnings-and-guidance trading event rather than a macro story.

03

What to watch

The article notes AZSTARYS contribution post-acquisition; traders may re-rate the stock if investors conclude the pain-portfolio headwinds are temporary and acquisition synergies offset them.

Relevance 9/10Novelty 8/10Timing: pre-open today, immediately after the Q2 results and full-year guidance update

Background

Collegium reported Q2 2026 results before the open and simultaneously trimmed full-year revenue guidance.

Company-level read

Ticker impact

$COLLBearishHigh confidence
Context

Collegium Pharmaceutical shares fell 13.2% pre-open after Q2 results and a full-year revenue outlook cut, despite EPS and EBITDA beats.

Expected impact

Near-term bias remains bearish while the market digests the lowered full-year revenue midpoint and ongoing generic-competition headwinds.

Evidence & confidence

The article cites a top-line miss versus consensus and a full-year revenue guidance midpoint about 3.4% below Street estimates, which typically outweighs adjusted EPS/EBITDA beats.

Market effects

Sector

Highlights ongoing pricing pressure from generics in specialty pain drugs, reinforcing caution on similar pain-portfolio revenue durability.

Regional

No specific regional spillover beyond a modest NASDAQ red backdrop.

Global

Limited; the catalyst is company-specific guidance and portfolio performance.

Counterpoint

What could challenge this read

The quarter showed adjusted EPS and EBITDA beats and strong JORNAY PM growth, so the guidance cut may reflect timing or conservatism rather than a structural demand collapse.

Key entities

  • company
    Collegium Pharmaceutical

    Specialty biopharmaceutical company whose Q2 results and full-year revenue guidance cut drove a sharp pre-open decline.

  • product
    BELBUCA

    Pain franchise product referenced as part of the portfolio facing generic-competition headwinds.

  • product
    Xtampza ER

    Pain franchise product referenced as part of the portfolio facing generic-competition headwinds.

  • product
    Nucynta franchise

    Pain franchise referenced as part of the portfolio facing generic-competition headwinds.

  • product
    JORNAY PM

    Pain product cited as rising 41% year-over-year to $46.1 million.

Read at source← All news

Related articles

AUG 6
$COLLHigh

COLLEGIUM PHARMACEUTICAL, INC (COLL): Results of Operations and Financial Condition

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 coll-2026x06x30xex99x1.htm EX-99.1 Document Exhibit 99.1 Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress – Completed Acquisition of AZSTARYS ® , Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Gener

SEC EDGAR 8-K7 min
MAY 27
$COLLHighAI 9/10

Why Collegium Pharmaceutical Inc. (COLL) Stock Is Gaining Attention for Its ADHD Portfolio

Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 2026 results on May 7, with revenue up 9% YoY to $193.5 million, beating the Street’s $187.4 million estimate. Adjusted EPS rose to $1.76 from $1.49 and topped expectations of $1.63. The company cited strong ADHD franchise growth, including Jornay PM sales up 36% YoY, and expects Jornay PM revenue of $190–$200 million in 2026. Collegium also plans to expand its ADHD portfolio via Azstarys acquisition, expecting it to add over $50 million to H2 2

finance.yahoo.com5 min
AUG 8
$DTMedAI 8/10

Dynatrace Springs on Q1 Figures

Dynatrace (NYSE: DT) reported Q1 FY2027 results for the quarter ended June 30, 2026. Total ARR was $2,136 million, up 17%. Total revenue rose to $555 million, up 16%. Subscription revenue was $530 million. GAAP operating income was $71 million and non-GAAP $162 million. CEO Rick McConnell cited 41% organic net new ARR growth and accelerating TTM growth.

baystreet.ca2 min
AUG 8
$DBXMed

Dropbox Shares Decline Despite Earnings Beat as Revenue Growth Disappoints

Dropbox (DBX) shares fell about 5% premarket to around $32.80 after Q2 2026 results. The company reported adjusted EPS of $0.75 vs $0.74 expected and revenue of $631.5M vs about $627M, but revenue rose only 0.9% year over year. Non-GAAP operating margin improved to 39.7%. Paying users reached 18.19M. William Blair upgraded to Market Perform, while consensus remains Sell.

yahoo.com4 min
AUG 8
$HLMedAI 8/10

Hecla Mining Q2 Earnings Call Highlights

Hecla Mining reported Q2 financial and operating updates. The company ended the quarter with $483 million cash, about $472 million net cash, and an essentially undrawn $225 million revolver. It projected 2026 free cash flow of about $500 million at $50 silver and $3,500 gold, and raised Greens Creek silver guidance to 8.0-8.3 million ounces. Production guidance was adjusted for Lucky Friday and Keno Hill.

yahoo.com7 min